SNP_ID	Allele	Gene	Drug	Evidence_level	Efficacy	Dosage	Toxicity	Genotype	Description
rs2108622	C > T	CYP4F2	acenocoumarol	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	acenocoumarol	Level 2A	-	decreased	-	AC	                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
rs1057910	A > C	CYP2C9	Antiinflammatory agents, non-steroids	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1042522	C > G	TP53	antineoplastic agents	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1057910	A > C	CYP2C9	celecoxib	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1057910	A > C	CYP2C9	celecoxib	Level 2A	-	decreased	-	AC	                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.
rs1042522	C > G	TP53	cisplatin	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1042522	C > G	TP53	cyclophosphamide	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1057910	A > C	CYP2C9	diclofenac	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1042522	C > G	TP53	fluorouracil	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1057910	A > C	CYP2C9	losartan	Level 3	decreased	-	-	AC	                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
rs1042522	C > G	TP53	paclitaxel	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs2108622	C > T	CYP4F2	phenprocoumon	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	phenytoin	Level 3	-	-	increased	AC	                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.
rs1799978	T > C	DRD2	risperidone	Level 2A	decreased	-	-	CC	                Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the TC And TT genotype.
rs1799978	T > C	DRD2	risperidone	Level 3	-	-	increased	CC	                Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1057910	A > C	CYP2C9	valproic acid	Level 3	-	-	increased	AC	                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.
rs7294	C > T	VKORC1	warfarin	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.
rs2108622	C > T	CYP4F2	warfarin	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	warfarin	Level 1A	-	decreased	increased	AC	                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.
